TGTX TG THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1001316 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY68.8%
TTM net income YoY-76.3%
TTM EPS YoY-75.8%
Revenue 3-yr CAGR67.9%
Net income 3-yr CAGR—
Margins
Gross margin82.7%
Operating margin21.5%
Net margin11.8%
FCF margin9.5%
EBITDA margin21.5%
Returns
ROE18.0%
ROA8.1%
ROIC (approx.)16.4%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets64.1%
Debt / equity1.30x
Current ratio4.50x
Interest coverage4.14x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio1.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $616.29M | $329.00M |
| Cost of revenue | $100.71M | $38.49M |
| Gross profit | $515.57M | $290.52M |
| R&D expense | $160.22M | $94.29M |
| SG&A expense | $232.03M | $154.30M |
| Operating income | $123.32M | $41.93M |
| Interest expense | $26.73M | $24.03M |
| Pretax income | $107.39M | $25.59M |
| Income tax | -$339.79M | $2.21M |
| Net income | $447.18M | $23.38M |
| EBITDA | $123.38M | $42.00M |
| EPS (basic) | 3.10 | 0.16 |
| EPS (diluted) | 2.77 | 0.15 |
| Weighted avg. shares (diluted) | 161.41M | 160.34M |
| Balance sheet | ||
| Cash & equivalents | $79.15M | $179.89M |
| Short-term investments | $62.82M | $131.11M |
| Receivables | $305.63M | $129.19M |
| Inventory | $125.59M | $110.46M |
| Current assets | $630.76M | $566.36M |
| Total assets | $1.06B | $577.69M |
| Current liabilities | $153.76M | $90.68M |
| Long-term debt | $245.65M | $244.43M |
| Total debt | $245.65M | $244.43M |
| Total liabilities | $415.23M | $355.33M |
| Shareholders' equity | $648.02M | $222.36M |
| Net debt | $166.50M | $64.53M |
| Shares outstanding | 155.31M | 155.84M |
| Cash flow statement | ||
| Operating cash flow | -$24.77M | -$40.52M |
| Capital expenditure | $214,000 | $45,000 |
| Free cash flow | -$24.99M | -$40.56M |
| Investing cash flow | $13.80M | -$1.04M |
| Financing cash flow | -$89.73M | $128.53M |
| Depreciation & amortization | $59,000 | $68,000 |
| Stock-based compensation | $64.67M | $42.54M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.